INTRODUCTION

Orthotopic heart transplantation (OHT) is associated with a high rate of conduction disturbances (CD). Among CD requiring permanent pacemaker (PPM) implantation, sinus node dysfunction (SND) is more frequent in the immediate posttransplant period, whereas atrioventricular conduction disturbances (AVCD) are more common in long-term follow-up. Previous studies have reported an incidence of PPM implantation in OHT of 2%–24% (Mallidi & Bates, 2017; Rivinius et al., 2019; Woo et al., 2008). Nevertheless,
rhythm disturbances occurring after OHT might be due to surgical trauma and may potentially subside over time, but data regarding the persistence of PPM in OHT and its influence on patient outcomes remain scarce. However, statistics have indicated that Germany is among the European countries with the highest rates of cardiac device implantations. (Raatikainen et al., 2015) When assessing PPM indication in OHT recipients, one should take into consideration that these patients have multiple comorbidities, often undergo invasive procedures, and are under lifelong immunosuppression, thus increasing their risk of potential device-related infections. (Paterson et al., 1998; Sherman-Weber et al., 2004)

Therefore, we sought to elucidate the extent to which patients who had undergone PPM implantation were pacemaker dependent (PD) in a very long-term follow-up after OHT. Additionally, we examined the prognostic relevance of PPM and PD.

2 | METHODS

We performed a retrospective analysis of patient data collected at the most recent follow-up in an outpatient setting. The on-site examination of OHT recipients was planned in 3-month intervals and consisted of a brief history, clinical examination, electrocardiogram, and laboratory testing at every presentation, whereas transthoracic echocardiogram and pacemaker interrogation were performed every 6 months.

Among the 185 OHT recipients, one patient was excluded from the analysis because of a follow-up <1 year. Additionally, one patient was not included, as the pacemaker dependence was secondary to AV node ablation in refractory atrial fibrillation (Figure 1). We identified 49 patients who had undergone PPM implantation. According to the results of the last device interrogation, patients with PPM were stratified into two groups: PD and non-PD. No need for pacing was defined as atrial and/or ventricular pacing percentages <0.1% at the last assessment. Furthermore, we differentiated between early-PPM (<1 year after OHT) and late-PPM implantation (≥1 year after OHT). The underlying rhythm disturbances were further subdivided into two groups – SND and AVCD (Figure 1).

Patients in whom PPM explanation was performed because of no need for pacing or device-related complications were included in the non-PD group (n = 5). Among these, device-related endocarditis was suspected in one subject and Twiddler’s syndrome was observed in a further case.

Additionally, in one case, a device explantation because of an infection with consequent reimplantation due to PD was performed.

The study was performed in compliance with the Declaration of Helsinki, and data sampling was approved by the local ethics committee (2019-021-f-S).

2.1 | Statistics

Statistical analysis was conducted in IBM SPSS Statistics software, version 27. Continuous variables were expressed as mean±standard deviation (SD) and were further assessed with Student’s t-test. Categorical variables were given as numbers and percentages and were tested by chi-square test. The evaluation of potential risk factors for pacemaker dependence was performed with univariable and multivariable cox-regression analyses. For all statistical analyses, p < .05 was defined as significant.

3 | RESULTS

3.1 | Demographics

The study population consisted of 183 patients with a mean follow-up of 15.0±6.8 years and a mean age at the time of OHT of 44.7±15.5 years. Approximately, one-fifth of the overall

FIGURE 1 Flowchart of the study. Data are presented as number (percentage). Abbreviations: AV-Node-Ablation - atrioventricular node ablation; OHT, orthotopic heart transplantation; PPM, permanent pacemaker; PD, pacemaker dependence.
3.2 | Transplantation technique and PPM

Bicaval transplant technique was associated with a higher rate of PPM implantation in a univariate logistic regression analysis (OR 3.0, 95% CI 1.26–7.29, p = .013), whereas in bicaval OHT, the need for PPM was significantly lower (OR 0.4, 95% CI 0.14–0.93, p = .035). A total approach was preferred only in a limited number of patients. However, we observed no relevant influence of the surgical blueprint on PD at the last follow-up (OR 0.7, 95% CI 0.12–4.17, p = .714 for bicalvarial and OR 3.0, 95% CI 0.32–27.67, p = .341 for bicaval transplant technique).

3.3 | Timing-related indication for PPM

We detected no indication-related influence on PD in the overall population. Nonetheless, after stratification according to the time point of PPM implantation, AVCD early after OHT were found to be more likely to resolve. In contrast, early SNDs were still associated with PD in more than 80% of the patients. These differences were not observed in late-PPM (Figure 3).

3.4 | Cardiac parameters and PPM

Regardless of PPM implantation or PD, there were no statistically significant intergroup disparities concerning the biventricular allograft function expressed as left ventricular ejection fraction (LVEF) and tricuspid annular plane systolic excursion (TAPSE). Additionally, we observed no correlation between the ventricular pacing percentage and the LVEF (p = .357). The N-terminal pro b-type natriuretic peptide (NT-proBNP) levels were also comparable between groups. Furthermore, an assessment of the device-related consequences on the functional status of the recipients according to the New York Heart Association (NYHA) classification revealed no relevant differences between the groups (Table 1), (The Criteria Committee of the New York Heart Association, 1994)

3.5 | CD in the non-PPM population

Regardless of PPM status, the rate of conduction disturbances was higher in the OHT recipients than in the general population. The most common CD in non-PPM patients was a right bundle branch block (RBBB) (n = 74, 55.2%), followed by a left anterior fascicular block (LAFB) (n = 23, 17.2%) and a first-degree atrioventricular block (AV block) (n = 7, 5.2%). A left bundle branch block was less frequent (n = 2, 1.5%).

3.6 | Long-term follow-up

Although we do not have data on the incidence of cardiac syncope following OHT, the mortality rate was higher in patients with PPM (15-year mortality rate in PPM 14.5% vs. 11.9% in the non-PPM population, p = .026). Furthermore, PPM requirement was found to be a significant factor influencing mortality in a long-term follow-up after OHT in a univariate (HR 1.9, 95% CI 1.1–3.5, p = .031) as well as in a multivariate logistic regression analysis after adjustment for CAV, transplant technique, and left ventricular ejection fraction (HR 2.0, 95% CI 1.1–3.7, p = .033). Nevertheless, we observed no relevant impact on cardiovascular death in the same setting (HR 2.1, 95% CI 0.8–5.7, p = .126), but on mortality due to systemic infections and septicemia (HR 5.1, 95% CI 1.4–18.1, p = .013). Furthermore, after stratification according to the time point of PPM implantation,
### TABLE 1  Patient characteristics

| Main patient characteristics | Non-PPM n = 134 (73.2) | PPM n = 49 (26.8) | p value |
|-----------------------------|-------------------------|--------------------|---------|
| **1. Demographics**         |                         |                    |         |
| Age at HTx, years           | 43.8 ± 15.8             | 47.2 ± 14.5        | .190    |
| Ischemic time, min<sup>a</sup> | 193.4 ± 51.7           | 179.6 ± 53.9      | .136    |
| Follow-up, years            | 15.3 ± 7.3              | 14.3 ± 5.1         | .289    |
| Donor age, years<sup>b</sup> | 30.79 ± 12.4           | 31.1 ± 15.1        | .906    |
| Male, n (%)                 | 106 (79.1)              | 40 (81.6)          | .836    |
| Survivors, n (%)            | 104 (77.6)              | 31 (63.3)          | .059    |
| **2. Pretransplant heart disease** |                       |                    |         |
| Ischemic cardiomyopathy, n (%) | 45 (33.6)               | 21 (42.9)          | .297    |
| Dilated cardiomyopathy, n (%) | 62 (46.3)              | 21 (42.9)          | .739    |
| Others, n (%)               | 27 (20.1)               | 7 (14.3)           | .520    |
| **3. Transplant technique** |                         |                    |         |
| Biatrial, n (%)             | 89 (66.4)               | 42 (85.7)          | .010*   |
| Bicaval, n (%)              | 37 (27.6)               | 6 (12.2)           | .031*   |
| Total, n (%)                | 8 (6.0)                 | 1 (2.0)            | .448    |
| **3. Rejections and CAV**   |                         |                    |         |
| Rejection episodes, n (%)   | 73 (54.5)               | 29 (59.2)          | .617    |
| Rejections requiring therapy, n (%) | 46 (34.3)            | 22 (44.9)          | .227    |
| CAV, n (%)                  | 51 (38.1)               | 27 (55.1)          | .044*   |
| **4. Clinical and laboratory examination** | | | |
| NYHA class >1, n (%)        | 101 (75.4)              | 38 (77.6)          | .847    |
| NT-proBNP, pg/ml            | 4094.2 ± 7668.4         | 6107.2 ± 8396.4   | .127    |
| **5. Echocardiographic assessment** | | | |
| LVEF, (%)                   | 57.1 ± 6.8              | 56.8 ± 9.4         | .835    |
| TAPSE, mm                   | 16.4 ± 3.6              | 16.1 ± 5.7         | .735    |

| Main patient characteristics | Non-PD n = 17 (34.7) | PD n = 32 (65.3) | p value |
|-----------------------------|----------------------|-----------------|---------|
| **1. Demographics**         |                       |                 |         |
| Age at HTx, years           | 44.2 ± 17.7           | 48.7 ± 12.5     | .307    |
| Ischemic time, min<sup>a</sup> | 167.4 ± 64.6          | 186.2 ± 46.9    | .268    |
| Follow-up, years            | 16.0 ± 4.8            | 13.4 ± 5.1      | .088    |
| Donor age, years<sup>b</sup> | 27.7 ± 13.3           | 32.8 ± 15.8     | .284    |
| Male, n (%)                 | 13 (76.5)             | 27 (84.4)       | .700    |
| Survivors, n (%)            | 11 (64.7)             | 20 (62.5)       | 1.000   |
| **2. Pretransplant heart disease** |                       |                 |         |
| Ischemic cardiomyopathy, n (%) | 8 (47.1)              | 13 (40.6)       | .765    |
| Dilated cardiomyopathy, n (%) | 5 (29.4)              | 16 (50.0)       | .229    |
| Others, n (%)               | 4 (23.5)              | 3 (9.4)         | .217    |
| **3. Transplant technique** |                       |                 |         |
| Biatrial, n (%)             | 15 (88.2)             | 27 (84.4)       | 1.000   |
| Bicaval, n (%)              | 1 (5.9)               | 5 (15.6)        | .650    |
| Total, n (%)                | 1 (5.9)               | 0 (0.0)         | .347    |
| **3. Rejections and CAV**   |                       |                 |         |
early-PPM was associated with poorer outcomes (HR 2.5, 95% CI 1.3–4.8, \( p = .004 \)), whereas late-PPM did not influence mortality (HR 1.2, 95% CI 0.4–3.3, \( p = .737 \); Figure 4).

4 | DISCUSSION

To our knowledge, this is the first study evaluating the potential prognostic effects of PPM in a very long-term follow-up after OHT. An additional advantage is the use of device interrogation data to assess the need for permanent pacing.

4.1 | A history lesson

As previously reported, biatrial OHT was associated with a higher rate of CD requiring PPM implantation, whereas in bicaval OHT, the incidence of CD was significantly lower.(Jones et al., 2011; Schnoor et al., 2007) No reliable statement can be made about the total transplant technique because our experience was limited to a small number of cases. On the one hand, this approach creates no anatomical substrate for CD, but on the other hand, it is often associated with a prolonged ischemic time with potential consequences for the graft function.(Morgan & Edwards, 2005) Although we did not observe relevant differences in donor age between groups, there was a larger gap in PD/non-PD compared to PPM/non-PPM, thus indicating the potential of advanced donor age to cause persistent CD. In addition, CAV was more prevalent in the PPM group indicating the potential of the ischemic injury to cause CD, but we observed relation to the type of CD in contrast to previous studies (\( p = .155 \)).(Cui et al., 2003)

4.2 | Timing and indication

In line with prior reports, approximately 25% of the patients required PPM, and the indication distribution was dominated by early SND and late AVCD.(Jones et al., 2011; Woo et al., 2008) Previous research on the role of the type and timing of CD in PPM have indicated that early CD are more likely to resolve and to not require PPM, whereas late CD were considered more persistent.(Rivinius et al., 2019) The indication paradox in our study may be due to the most frequent use of the biatrial approach and the higher incidence of associated CD. Additionally, 90% of the SNDs were diagnosed in patients with biatrial OHT, the transplant technique with the greatest potential to distort the atrial anatomy and disrupt the conduction pathways.

4.3 | PD in long-term follow-up

One-third of the patients (\( n = 17, 34.7\% \)), were non-PD in a quindecennial follow-up. We were unable to identify any prior research focusing on the prevalence of PD in a long-term follow-up after OHT. An assessment of the atrial and ventricular pacing percentages (PP) revealed a relatively higher need for atrial electrical support in SND in comparison to the ventricular pacing percentages in AVCD (46.9 ± 40.6 vs. 24.0 ± 34.8, respectively), justifying the need for pacing in early and proximally located CD as previously reported.(Rivinius et al., 2019) The higher need for atrial support can be explained not only by significant bradycardia due to SND but also by the chronotropic incompetence of allografts.(Melton et al., 1999)
Antecedent research regarding the prognosis in PPM was contradictory. (Cantillon et al., 2010; Rivinius et al., 2019) In comparison, our analysis of a very long-term follow-up after OHT showed PPM to be associated with poorer outcomes in univariate and multivariate logistic regression analyses. Nevertheless, as 90.0% of the SND and 87.9% of all CD requiring PPM were observed in biatrial OHT, the inferior prognosis might also be related to biatrial approach, although no explicit prognostic relevance was observed. Interestingly, after stratification according to the leading causes of death, we observed a significant correlation between PPM and septicemia but not with cardiovascular endpoints. Although we have no evidence for a direct association between the bloodstream infection and the device leads, implants in immunosuppression are, as known, associated with a higher mortality risk. (Paterson et al., 1998; Sherman-Weber et al., 2004)

4.5 Observation period and PPM incidence

The recent guidelines on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology advocate an observational period of at least 6 weeks for CD and chronotropic incompetence after heart transplantation. (Glikson et al., 2022) In contrast, according to the guidelines on cardiac pacing published in 2013, a period of clinical observation from 5 days up to some weeks was recommended. (European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA) & Brignole, 2013) The extended observational period in the recent era may result in a lower rate of PPM requirement and in a preselection of the cases with persistent conduction disturbances in the immediate posttransplant period and beyond. Since we report on long-term outcomes, most of our patients were transplanted in the first decade of the twenty first century. Thus, we gain a precious insight into the consequences of the recommendations in the earlier era. Additionally, we recognize how much progress has been made in this field in the last years.

5 LIMITATION AND STRENGTHS OF THE STUDY

The main limitation of our study is the small number of patients who had undergone device implantation. Additionally, there were insufficient data regarding the pretransplant factors, which might have a relevant influence on the posttransplant care and outcome. Nevertheless, when justifying the need for pacing in OHT and its consequences in follow-up, we provide evidence based on echocardiographic and device assessment. Additionally, the evaluation of all factors was performed in an incomparable long-term follow-up after OHT.

6 CONCLUSIONS

One-third of the OHT recipients with PPM are non-PD in a long-term follow-up. However, PPM requirement is associated with poorer outcomes and correlates with fatal infectious complications. Notably, among the indications for PPM, the early SNDs are not only the most prominent but also the most persistent CD. Nevertheless, PPM implantation remains a case-by-case consideration because the donor and recipient determinants deliver no additional aid in identifying the subjects who might not require pacing in follow-up. The
surgical scar connecting the donor and recipient atria endure as the only factor, with unquestionable potential in building a bridge between the intrinsic conduction pathway and the device leads.

ACKNOWLEDGEMENTS
Open Access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST
The authors have no financial interests related to this manuscript.

AUTHOR CONTRIBUTIONS
EA conception and design of the work, interpretation of the data, drafting the initial manuscript. CP, ADA and GF critical revision of the draft, IT, HR and JS supervision, interpretation of the data, critical revision for important intellectual content. All authors read and approved the version to be published.

ETHICAL APPROVAL
The study was performed in compliance with the Declaration of Helsinki, and data sampling was approved by the local ethics committee (2019-021-f-S).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Emyal Alyaydin https://orcid.org/0000-0001-5139-604X
Izabela Tuleta https://orcid.org/0000-0002-8482-591X

REFERENCES
Cantillon, D. J., Tarakji, K. G., Hu, T., Hsu, A., Smedira, N. G., Starling, R. C., Wilkoff, B. L., & Saliba, W. I. (2010). Long-term outcomes and clinical predictors for pacemaker-requiring bradycardia after cardiac transplantation: Analysis of the UNOS/OPTN cardiac transplant database. Heart Rhythm, 7(11), 1567–1571.

Cui, G., Kobashigawa, J., Margarian, A., & Sen, L. (2003). Cause of atrioventricular block in patients after heart transplantation. Transplantation, 76(1), 137–142.

European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA), Brignole, M., Auricchio, A., Baron-Esquivias, G., Bordachar, P., Boriani, G., Breithardt, O. A., Cleland, J., Dehardo, J. C., Delgado, V., Elliott, P. M., Gorenek, B., Israel, C. W., Leclercq, C., Linde, C., Mont, L., Padeletti, L., Sutton, R., & Vardas, P. E. (2013). ESC guidelines on cardiac pacing and cardiac resynchronization therapy: The task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European heart rhythm association (EHRA). Europace, 15(8), 1070–1118.

Glikson, M., Nielsen, J. C., Kronborg, M. B., Michowitz, Y., Auricchio, A., Barbash, I. M., Barrabés, J. A., Boriani, G., Braunschweig, F., Brignole, M., Burri, H., Coats, A. J., S., Dehardo, J. C., Delgado, V., Diller, G. P., Israel, C. W., Keren, A., Knops, R. E., Kotecha, D., ..., ESC Scientific Document Group. (2022). 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the task force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European heart rhythm association (EHRA). Revista Española de Cardiología (Engl Ed), 75(5), 430.

Jones, D. G., Mortsell, D. H., Rajaruthnam, D., Hamour, I., Hussain, W., Markides, V., Banner, N. R., & Wong, T. (2011). Permanent pacemaker implantation early and late after heart transplantation: Clinical indication, risk factors and prognostic implications. The Journal of Heart and Lung Transplantation, 30(11), 1257–1265.

Mallidi, H. R., & Bates, M. (2017). Pacemaker use following heart transplantation. The Ochsner Journal, 17(1), 20–24.

Mehra, M. R., Crespo-Leiro, M. G., Dipchand, A., Ensminger, S. M., Hiemann, N. E., Kobashigawa, J. A., Madsen, J., Parameshwar, J., Starling, R. C., & Uber, P. A. (2010). International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010 [published correction appears in J Heart Lung Transplant. 2011 Mar;30(3):360]. The Journal of Heart and Lung Transplantation, 29(7), 717–727.

Melton, I. C., Gilligan, D. M., Wood, M. A., et al. (1999). Optimal cardiac pacing after heart transplantation. Pacing Clin Electrophysiol, 22(10), 1510–1527.

Morgan, J. A., & Edwards, N. M. (2005). Orthotopic cardiac transplantation: Comparison of outcome using biatrial, bicaval, and total techniques. Journal of Cardiac Surgery, 20(1), 102–106.
Paterson, D. L., Dominguez, E. A., Chang, F. Y., Snydman, D. R., & Singh, N. (1998). Infective endocarditis in solid organ transplant recipients. *Clinical Infectious Diseases, 26*(3), 689–694.

Raatikainen, M. J., Arnar, D. O., Zeppenfeld, K., Merino, J. L., Levya, F., Hindriks, G., & Kuck, K. H. (2015). Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European heart rhythm association. *Europace, 17*(suppl 1), i1–i75.

Rivinius, R., Helmschrott, M., Rahm, A. K., Darche, F. F., Thomas, D., Bruckner, T., Doesch, A. O., Ehlermann, P., Katus, H. A., & Zitron, E. (2019). Risk factors and survival of patients with permanent pacemaker implantation after heart transplantation. *Journal of Thoracic Disease, 11*(12), 5440–5452.

Schnoor, M., Schäfer, T., Lühmann, D., & Sievers, H. H. (2007). Bicaval versus standard technique in orthotopic heart transplantation: A systematic review and meta-analysis. *The Journal of Thoracic and Cardiovascular Surgery, 134*(5), 1322–1331.

Sherman-Weber, S., Axelrod, P., Suh, B., Rubin, S., Beltramo, D., Manacchio, J., Furukawa, S., Weber, T., Eisen, H., & Samuel, R. (2004). Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. *Transplant Infectious Disease, 6*(4), 165–170.

Stewart, S., Winters, G. L., Fishbein, M. C., Tazelaar, H. D., Kobashigawa, J., Abrams, J., Andersen, C. B., Angelini, A., Berry, G. J., Burke, M. M., Demetris, A. J., Hammond, E., Itescu, S., Marboe, C. C., McManus, B., Reed, E. F., Reinsmoen, N. L., Rodriguez, E. R., Rose, A. G., ...Billingham, M. E. (2005). Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *The Journal of Heart and Lung Transplantation, 24*(11), 1710–1720.

The Criteria Committee of the New York Heart Association. (1994). *Nomenclature and criteria for diagnosis of diseases of the heart and great vessels* (9th ed., pp. 253–256). Little Brown & Co.

Woo, G. W., Schofield, R. S., Pauly, D. F., Hill, J. A., Conti, J. B., Kron, J., Klodell, C. T., Singh, R., & Aranda, J. M. (2008). Incidence, predictors, and outcomes of cardiac pacing after cardiac transplantation: An 11-year retrospective analysis. *Transplantation, 85*(8), 1216–1218.

---

**How to cite this article:** Alyaydin, E., Pogoda, C., Dell’Aquila, A., Frommeyer, G., Sindermann, J. R., Reinecke, H., & Tuleta, I. (2022). Permanent pacing in a very long-term follow-up after orthotopic heart transplantation: A matter of when or why? *Annals of Noninvasive Electrocardiology, 27*, e12979. [https://doi.org/10.1111/anec.12979](https://doi.org/10.1111/anec.12979)